

Atty Docket No. 19452A-000320US

PTO FAX NO.: 703-872-9306

ATTENTION: Examiner Zara, Jane J.

Group Art Unit 1635

**OFFICIAL COMMUNICATION**  
**FOR THE PERSONAL ATTENTION OF**  
**EXAMINER Zara, Jane J.**

**CERTIFICATION OF FACSIMILE TRANSMISSION**


I hereby certify that the following documents in re Application of MARTH and ELLIES, Application No. 09/856,391, filed January 7, 2002 for USE OF CORE 2 GLCNAC TRANSFERASE INHIBITORS IN TREATING INFLAMMATION are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Documents Attached

1. Notice of Appeal
2. Petition for Extension of Time Under 37 CFR 1.136(a)

Number of pages being transmitted, including this page: 3



Dated: April 19, 2005

  
Stephanie J. Whitehurst

***PLEASE CONFIRM RECEIPT OF THIS PAPER BY  
RETURN FACSIMILE AT (415) 576-0300***

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, CA 94111-3834  
Telephone: 415-576-0200  
Fax: 415-576-0300  
0106

PTO/SB/31 (09-04)

NOTICE OF APPEAL FROM THE EXAMINER TO THE BOARD OF PATENT APPEALS AND INTERFERENCES		Docket Number (Optional) 19452A-000320US	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>April 19, 2005</u>  Signature   Typed or printed name <u>Stephanie J. Whitehurst</u>		In re Application of <u>MARTH and ELLIES</u>	
		Application Number <u>09/856,391</u>	Filed <u>January 7, 2002</u>
		For <u>USE OF CORE 2 GLCNAC TRANSFERASE INHIBITORS IN TREATING INFLAMMATION</u>	
		Art Unit <u>1635</u>	Examiner <u>Zara, Jane J.</u>
Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision of the examiner.			
The fee for this Notice of Appeal is (37 CFR 41.20(b)(1))		\$ <u>500</u>	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee shown above is reduced by half, and the resulting fee is:		\$ <u>250</u>	
<input type="checkbox"/> A check in the amount of the fee is enclosed.			
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.			
<input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account. I have enclosed a duplicate copy of this sheet.			
<input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. <u>20-1430</u> . I have enclosed a duplicate copy of this sheet.			
<input type="checkbox"/> A petition for an extension of time under 37 CFR 1.136(a) (PTO/SB/22) is enclosed.			
<b>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</b>			
I am the		 Signature	
<input type="checkbox"/> applicant/inventor.		Kevin Baetan Reg. No. 34,774 Typed or printed name	
<input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)			
<input checked="" type="checkbox"/> attorney or agent of record. Registration number <u>34,774</u>		415-576-0200 Telephone number	
<input type="checkbox"/> attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34. _____		April 19, 2005 Date	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.			

☒ \*Total of 2 forms are submitted.

v